Investigations on the therapeutic regimen of a novel non-steroidal anti-inflammatory drug, the UHAC62 capsule

Autor: Teruhiko Suzuki, Masako Hara, Mitsuyoshi Nakashima, Shoichiro Irimajiri, Miyako Ishigami, Takeshi Tojo, Toru Hayashi, Atsushi Suzuki, Fumihiko Imai, Wataru Hirose, Sadao Kashiwazaki, Haruaki Warabi, Yasuo Matsuoka, Yoshinari Takasaki, Mitsuhiro Kawagoe, Ayako Nakajima, Sachiko Sugawara
Rok vydání: 1997
Předmět:
Zdroj: Ensho. 17:173-193
ISSN: 1884-4006
0389-4290
Popis: A double-blind comparative study among 9 medical centers was conducted in order to investigate the optimal daily administration schedule of UHAC62 (Generic name: Meloxicam), a kind of non-steroidal anti-inflammatory oxycam agent. The daily 10 mg of UHAC62, which had been considered as an optimal dose, was administered either once daily, immediately after supper (Group O), or given twice a day divided into 5 mg immediately after breakfast and supper (Group T), both for weeks to patients with rheumatoid arthritis.Out of the total 52 patients, 1 patient was excluded from the analyses; and 41 patients (Group O: 23 cases, Group T: 18 cases), 51 patients (Group O: 27 cases, Group T: 24 cases) and 44 patients (Group O: 24 cases, Group T: 20 cases) were subjected to the ratings of Final Global Improvement, Overall Safety, and Usefulness, respectively. The results showed the following:(1) The ratio of the patients who showed a better than “Moderate Improvement” in the Final Global Improvement Rating was 30.4 % and 27.8 % in the Group O and Group T, respectively.(2) The ratio of the patients on whom the test drug was shown to be “Completely Safe” in the Overall Safety Rating was 88.9% and 91.7% in the Group O and Group T, respectively. All of the adverse drug reactions which were seen in the patients of Group O and the 2 patients of the Group T were assessed as “mild”.(3) The ratio of the patients on whom the test drug was rated as better than “Useful” was 29.2% and 25.0 % in the Group O and Group T, respectively.There was no significant difference in the overall evaluations and the improvement rating of the symptoms between the groups.According to these results, it was considered that the once daily administration of UHAC62 might be more promising for materializing a higher compliance in the patients who need long-term administration, although both regimens, the once and the twice daily administrations are applicable.
Databáze: OpenAIRE
Externí odkaz: